Life Sciences

Welcome to the 'Life Sciences' tag page at Technorati. This page features content from the farthest reaches of the Blogosphere that authors have "tagged" with 'Life Sciences'.

Latest blogosphere posts tagged “Life Sciences”

• Secure Tracking and Tracing using GS1 and SAP OER - Leverage GS1 EPCIS in Healthcare -- EPISODE I

  
  SAP Developer Network SAP Weblogs — Authority: 153
  In this new blog series I will write about GS1 in Healthcare, what we did, how our prototype looks like and, most importantly, the benefits of this solution.
  1 hour ago

• Pathway Founder Gets Startup Itch, Ekos Endures Tough Year, EndoGastric Bags $21.5M, & More Seattle-Area Life Sciences News

  
  Xconomy — Authority: 674
  Roundup , Biotech , people Luke Timmerman wrote: Seattle biotechies must have gorged on too much turkey in the holiday week, because the news was slow, slow, slow this week. But there were a few interesting things to say about medical devices. — Tom Clement , the founder of Kirkland, WA-based Pathway ...
  5 hours ago

• Phenomix Strikes European Partnership for Diabetes Drug, Potentially Worth $163M

  
  Xconomy — Authority: 674
  Biotech , diabetes , deals Luke Timmerman wrote: Phenomix has found a partner to help it develop a diabetes drug in Europe and certain other countries. The San Diego-based biotech company said today that the Italy-based Chiesi Farmaceutici has agreed to pay $28 million in near-term cash and equity ...
  20 hours ago

• The State of High-Tech and Life Sciences Executive Compensation Quiz: Answers and A Bit of Perspective on What You Can Expect in 2010

  
  Xconomy — Authority: 674
  X Factor , Executive Pay , startups Robert Buderi wrote: The end of the year is a time when compensation is on a lot of people’s minds—particularly with company committees busy working to set executive salary, bonus, and equity compensation for the coming year. Last week, I gauged Xconomy ...
  23 hours ago

• Forma Gets a $25.5M Fix, Novartis Bids Idera Adieu, Alnylam CEO Talks Strategy, & More Boston-Area Life Sciences News

  
  Xconomy — Authority: 674
  Roundup , Life Sciences , Alliances Rebecca Zacks wrote: Somewhere between the turkey prep and the post-pie catatonia, folks at New England’s life sciences companies managed to make some news. —Idera Pharmaceuticals (NASDAQ: IDRA ), a developer of DNA- and RNA-based drugs, announced that Swiss drug ...
  1 day ago

• Quick Take: Novartis Vaccine Chief Andrin Oswald on Swine Flu and Vaccine Business

  
  Xconomy — Authority: 674
  Life Sciences , vaccines , H1N1 Swine Flu Ryan McBride wrote: It’s been a year since Andrin Oswald took over as CEO of Novartis Vaccines and Diagnostics, the 5th-largest vaccine business in the world, headquartered right here in Cambridge, MA. I met up with Oswald before he gave a keynote speech at a ...
  1 day ago

• Partnershps in Clinical Trials Asia Pacific: Asia’s Pharma industry – Innovative Drug Development

  
  Partnerships in Clinical Trials — Authority: 124
  Albert G.S. Liou , Corporate Vice President and General Manager, Asia-Pacific Region, PAREXEL INTERNATIONAL, Taiwan Melvin Toh , Vice President, Pharmaceutical Development, CK LIFE SCIENCES, Hong Kong Fidela Ll. Moreno, MD, Vice President, Global Development Operations, Clinical Site Management and Monitoring, ...
  1 day ago

• Dyax Shares Rocket as FDA Clears Treatment for Rare Inflammatory Disease

  
  Xconomy — Authority: 674
  Biotech , Drugs , FDA Luke Timmerman wrote: Dyax got some good news late today that sent shares booming. The Cambridge, MA-based company (NASDAQ: DYAX ) said it has received FDA clearance to start selling a drug that treats hereditary angioedema, a rare genetic condition in which people get rapid ...
  1 day ago

• Santarus Shares Boom on FDA Approval of Over-the-Counter Heartburn Drug

  
  Xconomy — Authority: 674
  Biotech , Drugs , Heartburn Luke Timmerman wrote: San Diego-based Santarus (NASDAQ: SNTS ) got some good news late today. The company’s partner, the Schering-Plough unit of Merck, has gotten clearance from the FDA to start selling an over-the-counter version of Santarus’ fast-acting heartburn ...
  1 day ago

• Genzyme Resumes Shipments of Gaucher’s Drug from Allston Plant

  
  Xconomy — Authority: 674
  Gauchers Disease , FDA , biomanufacturing Ryan McBride wrote: Genzyme (NASDAQ: GENZ ) says today that it has begun shipments of its best-selling drug for Gaucher’s disease made at its plant in the Allston neighborhood of Boston. There have been shortages of the drug since the firm halted production ...
  1 day ago

• For medical device entrepreneurs, an office hours opportunity from MassMedic

  
  Innovation Economy — Authority: 513
  More events worth knowing about on the Open Office Hours front, this time from the Massachusetts Medical Device Industry Council , a/k/a MassMedic... Amy Frederick wrote in yesterday to make sure I knew about a mentoring program she runs within MassMedic called MedTech Ignite, which aims to create high-powered ...
  1 day ago

• Genzyme Competitor Lands Pfizer Deal

  
  Xconomy — Authority: 674
  Life Sciences , deals , Gauchers Disease Ryan McBride wrote: Israel-based Protalix Biotherapeutics (NYSE: PLX ) said today it has struck a deal with drug giant Pfizer to develop and market Protalix’s experimental Gaucher’s disease drug, taliglucerase alfa. The drug, which the FDA has granted a ...
  1 day ago

• Forma Therapeutics Snags $25.5M Venture Round, Punctuating Startup’s Breakout Year

  
  Xconomy — Authority: 674
  Biotech , VC , deals Luke Timmerman wrote: Anybody drawing up a list of New England’s biotech companies that really broke through in 2009 would have to consider Forma Therapeutics . The Cambridge, MA-based startup has nailed down a $25.5 million Series B venture round, which means it has now raised a ...
  2 days ago

• San Diego Biotech Leaders on the Future of Stem Cells, MicroRNA, & Cancer Biology

  
  Xconomy — Authority: 674
  Biotech , people , Xconomy Luke Timmerman wrote: San Diego has some of the most intriguing biotech companies in the world, and one of the things I’ve noticed is that they aren’t all packed in one neighborhood where everyone can mingle. So we at Xconomy are thrilled that we are about two weeks away ...
  2 days ago

• Tech Executive Pay Raises Way Down, New Study Says

  
  Xconomy — Authority: 674
  ceos , people , executive compensation Ryan McBride wrote: Technology executive pay raises in 2009 have taken their biggest nosedive of the past decade, according to a new compensation study. The study, which polled privately held firms from around the U.S., indicates that the current economic downturn ...
  2 days ago

• ClearCount Nabs Popular Science’s “Best of What’s New” Award

  
  TECHburgher :: Putting some sizzle in the Pittsburgh technology sector. — Authority: 132
  The editors of Popular Science have named Pittsburgh-based ClearCount’s SmartSponge® System one of the top technology innovations of 2009. As a winner off a “Best of What’s New” award in the health category , the SmartSponge System stands out as the first and only system to incorporate the efficiency ...
  2 days ago

• EPO Awards 3 Patents to 3 Suven Drugs

  
  Stock Watch - Stock Specific News — Authority: 149
  As has been confirmed by the company, drug-maker Suven Life Sciences has been awarded patents by the European Patent Office for as many as 3 of its chemical entities, used in drugs which are mainly for treatment of nerve disorders. "The company gets three patents -- EP1537113, EP1704154 and EP1856132 and the said ...
  2 days ago

• Ekos, Enduring Tough Year for Devices, Sticks With Goal to Break Even Next Year

  
  Xconomy — Authority: 674
  Biotech , Ultrasound , Devices Luke Timmerman wrote: Ekos is on a quest to change the way doctors think about how to best dissolve blood clots. Like a lot of bold visions, this hasn’t happened overnight or without some bumps along the way. But even in a very tough year for new medical devices, the ...
  3 days ago

• A Smarter War on Cancer

  
  Xconomy — Authority: 674
  Biotech , cancer , Drugs Tony Blau wrote: [ Editors Note: this editorial was co-authored by Jay (Marty) Tenebaum of CollabRx and Leroy Hood of the Institute for Systems Biology .] One of society’s great challenges is to advance health care while deflecting its rising cost. Achieving this objective ...
  3 days ago

• Hyper-Analytical “Insanity” Cripples Drug R&D, Says Alnylam CEO John Maraganore

  
  Xconomy — Authority: 674
  Biotech , people , management Luke Timmerman wrote: There’s one thing drug makers love to use to figure out which drugs to invest in: spreadsheets. Not Alnylam Pharmaceuticals, though. Estimates of future cash flows and other financial analysis tools are one of the big reasons why drugmakers spend so ...
  3 days ago

Comments about Life Sciences